Evidence map›Paper›PMID 42165362›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026

Plasminogen Activator Inhibitor-1 is Internalized by Endothelial Cells via A Pinocytosis-Like Mechanism and Evades Degradation.

Molly McAdow, Gjina Ahmetaj, Rachel Hauschel, Anne Eichmann, William Sessa

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Molly McAdowDepartment of Obstetrics, Gynecology, & Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut, USA.ORCID https://orcid.org/0000-0001-5701-6984
Gjina AhmetajDepartment of Obstetrics, Gynecology, & Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut, USA.ORCID https://orcid.org/0009-0004-1094-0255
Rachel HauschelDepartment of Obstetrics, Gynecology, & Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut, USA.ORCID https://orcid.org/0009-0005-1195-8171
Anne EichmannDepartment of Molecular and Cellular Physiology, Yale University School of Medicine, New Haven, Connecticut, USA.ORCID https://orcid.org/0000-0001-5563-210X
William SessaDepartment of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA.ORCID https://orcid.org/0000-0001-5759-1938

Funding

Plasminogen activator inhibitor 1 (PAI1) as a therapeutic target for maternal endothelial dysfunction in preeclampsiaR01HL181577 · NHLBI · YALE UNIVERSITY · PI Molly E McAdow · 2025 to 2026
$1.6M
Albert McKern Scholar Award from the Yale University Department of Obstetrics, Gynecology, and Reproductive SciencesDoris Duke Charitable Foundation Fund to Retain Clinical Scientists 2020145Foundation for Society of Maternal Fetal Medicine and the American Association of Obstetricians and Gynecologists FoundationNHLBI NIH HHS R01 HL181577NIH/NICHD 1R01HL181577-01Yale Physician Scientist Development
6 · The paper itself

Abstract

Plasminogen activator inhibitor 1 (PAI1) is a secreted protease inhibitor, but accumulating evidence supports a role for PAI1 in regulating intracellular processes. PAI1 is secreted in an active conformation that serves as a bait for plasminogen activators (PA). Interaction between PAs and PAI1 results in a covalent linkage. PAI1/PA bind LRP1 and uPAR on the cell surface, triggering internalization and degradation. However, it was recently shown that exogenous PAI1 directly interacts with endothelial nitric oxide synthase inside endothelial cells. Our objective was to characterize the non-degradative pathway for PAI1 internalization. We use a hemagglutinin (HA)-tagged construct of PAI1 to track endocytosis of exogenous PAI1 in cultured endothelial cells via Western blotting of cell lysates and immunofluorescence microscopy. We demonstrate that PAI1-HA is actively internalized through a non-receptor-mediated mechanism, independent of clathrin-mediated endocytosis or caveolae. PAI1-HA internalization was partially inhibited by a derivative of amiloride, an inhibitor of macropinocytosis, though it was independent of Rac1 and CDC42, GTPases used for macropinocytosis. After internalization, PAI1-HA evades degradation for at least 3 h. By contrast, PAI1/uPA is degraded within 30 min of internalization. PAI1-HA internalization is independent of LRP1 and uPAR. We propose a model whereby PAI1/PA is endocytosed by LRP1- and uPAR-dependent endocytosis, whereas latent PAI can be internalized through a pinocytic-like mechanism and evade degradation, facilitating paracrine signaling.

Indexed as

Endothelial CellsPinocytosisPlasminogen Activator Inhibitor 1Animalscdc42 GTP-Binding ProteinCells, CulturedEndocytosisHumansProteolysiscdc42 GTP-Binding ProteinPlasminogen Activator Inhibitor 1SERPINE1 protein, humancell signalingendothelial cellmacropinocytosisPAI1PAI1/uPAplasminogen activator inhibitor 1serpine1

Identifiers

PMID42165362
PMCPMC13283470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.